Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617661 | 0.85 | MBOAT4 (0.30) | MBOAT4 | |
| SCHEMBL1617136 | 0.76 | DHFR (0.33) | — | |
| SCHEMBL14989088 | 0.75 | TLR7 (0.36) | MBOAT4 | |
| SCHEMBL605039 | 0.68 | HRH4 (0.38) | — | |
| SCHEMBL13189157 | 0.67 | NAMPT (0.34) | — | |
| SCHEMBL602708 | 0.65 | NOS1 (0.37) | — | |
| SCHEMBL1512058 | 0.65 | DHFR (0.35) | — | |
| SCHEMBL29763294 | 0.64 | PIK3CA (0.33) | — | |
| Hydrochloric Acid SCHEMBL5626676 | 0.61 | — | — | |
| SCHEMBL3431694 | 0.61 | ACVR2A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | claimed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | claimed |
| EP-2124560-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | claimed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | claimed |
| US-8716475-B2 | 2-aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2599386-A1 | 2-aminopyrimidine modulators of the histamine h4 receptor | Janssen Pharmaceutica N.V. (BE) | 2013-06-05 | — | — | EP | disclosed |
| US-8415366-B2 | 2-aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-09 | — | — | US | disclosed |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janseen Pharmaceutiacal NV | 2011-09-08 | — | — | US | disclosed |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV | 2011-06-30 | — | — | US | disclosed |
| US-7923451-B2 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-12 | — | — | US | disclosed |
| EP-2124560-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158259-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | MBOAT4 4813/4885 |
| US-20110160451-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | MBOAT4 4813/4885 |
| US-20110218338-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | MBOAT4 4837/4885 |
| US-20080194577-A1 | Antiallergens; asthma; autoimmune disease; pruritius; antiarthritic agents | HRH4, HRH2, HRH3 | MBOAT4 4701/4885 |
| US-20130158258-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | MBOAT4 4813/4885 |
| US-20110160452-A1 | 2-Aminopyrimidine modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | MBOAT4 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.